Structural basis of Fabry disease
- PMID: 12359124
- DOI: 10.1016/s1096-7192(02)00151-8
Structural basis of Fabry disease
Abstract
Fabry disease is a lysosomal storage disease caused by deficiency in the enzyme alpha-galactosidase (alpha-GAL). To understand the molecular defects responsible for Fabry disease, we have collected more than 190 reported point and stop mutations and mapped them onto a model of human alpha-GAL based on the X-ray structure of the closely related enzyme alpha-N-acetylgalactosaminidase (alpha-NAGAL). The locations of the human alpha-GAL point mutations reveal two major classes of Fabry disease protein defects: active site mutations and folding mutations. Active site mutations reduce enzymatic activity by perturbing the active site without necessarily affecting the overall alpha-GAL structure. Folding mutations reduce the stability of alpha-GAL by disrupting its hydrophobic core. Examining the frequency of mutation around each alpha-GAL residue identifies the active site as a hotspot for mutations leading to Fabry disease. This study furthers our understanding of the structural basis for mutations leading to Fabry disease, from which new avenues for the treatment of lysosomal storage diseases may be developed.
Similar articles
-
The molecular defect leading to Fabry disease: structure of human alpha-galactosidase.J Mol Biol. 2004 Mar 19;337(2):319-35. doi: 10.1016/j.jmb.2004.01.035. J Mol Biol. 2004. PMID: 15003450
-
Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele.Hum Mutat. 2003 Dec;22(6):486-92. doi: 10.1002/humu.10275. Hum Mutat. 2003. PMID: 14635108
-
Catalytic mechanism of human alpha-galactosidase.J Biol Chem. 2010 Feb 5;285(6):3625-3632. doi: 10.1074/jbc.M109.060145. Epub 2009 Nov 25. J Biol Chem. 2010. PMID: 19940122 Free PMC article.
-
[Fabry disease (alpha-galactosidase deficiency)].Nihon Rinsho. 1995 Dec;53(12):2952-9. Nihon Rinsho. 1995. PMID: 8577042 Review. Japanese.
-
[alpha-Galactosidase gene mutation and its expression product in Fabry disease (alpha-galactosidase deficiency)].Rinsho Byori. 1997 Feb;45(2):127-35. Rinsho Byori. 1997. PMID: 9120996 Review. Japanese.
Cited by
-
Fabry Disease with Pacemaker Implantation as the Initial Event.Intern Med. 2019 Oct 15;58(20):2993-3000. doi: 10.2169/internalmedicine.2468-18. Epub 2019 Jun 27. Intern Med. 2019. PMID: 31243236 Free PMC article.
-
A pharmacogenetic approach to identify mutant forms of α-galactosidase A that respond to a pharmacological chaperone for Fabry disease.Hum Mutat. 2011 Aug;32(8):965-77. doi: 10.1002/humu.21530. Epub 2011 Jul 12. Hum Mutat. 2011. PMID: 21598360 Free PMC article.
-
Correlation of enzyme activities and genotype with clinical manifestations in Chinese patients of different sexes with classical and late-onset Fabry disease.Front Med. 2025 Jun;19(3):523-537. doi: 10.1007/s11684-025-1131-9. Epub 2025 May 13. Front Med. 2025. PMID: 40358875
-
Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin.Biochem J. 2007 Sep 1;406(2):285-95. doi: 10.1042/BJ20070479. Biochem J. 2007. PMID: 17555407 Free PMC article.
-
α-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants.J Biol Chem. 2012 Aug 17;287(34):28386-97. doi: 10.1074/jbc.M112.351056. Epub 2012 Jul 6. J Biol Chem. 2012. PMID: 22773828 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical